La catena delle opzioni mostra i dati chiave delle opzioni azionarie di MiNK Therapeutics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per MiNK Therapeutics..

MiNK Therapeutics (NASDAQ:INKT) Azioni, Catena delle Opzioni

MiNK Therapeutics

MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T-cell therapies to treat cancer and other life-threatening illnesses.

MiNK Therapeutics Inc

Outlook
Over the last several months, the beauty market has maintained solid momentum, though growth has moderated from the outsized double-digit growth of the last few years. Prestige fragrances remain an outperforming category, though growth has moderated by a couple of points exiting Q1. Mass beauty is now growing in the low single digits, with flattish performance in the mass cosmetics category. Within this backdrop, slower end demand and significant channel shifts in U.S. mass beauty and in Asia, are continuing to weigh on order levels into Q2, with sell-in tracking well below sell-out. As a result of these factors, Coty expect LFL sales growth in the first half of 3-4%.
The pace of category growth and consumer demand during the critical holiday period remains the central factor influencing the outlook for the second half, including retailer inventory levels and pace of re-orders. At present, Coty anticipates LFL growth in the second half to be relatively consistent with the first half, reflecting easier prior year comparisons and solid prestige fragrance performance on the one hand, and continued pressure in the Chinese mainland, Asia Travel Retail and U.S. mass cosmetics on the other hand.
In this very dynamic beauty market environment, Coty is future proofing its organization and processes to better capture new opportunities, respond to changes in the market with more agility, and solidify Coty's position as a beauty leader over the long term. Many of the workstreams are already under way, with an acceleration now in the timing of delivery, while others are newly initiated. Through the combination of these efforts, Coty now anticipates FY25 savings of over $120 million, an increase of over $45 million versus its initial target. And importantly, these projects should continue to deliver savings in FY26 and beyond.
Through the combination of continued sales growth, continuous gross margin expansion and increased cost savings for FY25 and beyond, while maintaining A&amp;CP in the high 20s percentage, Coty expects FY25 adjusted EBITDA to grow near the lower end of its prior guidance of +9-11% YoY. This outlook includes resumed adjusted EBITDA growth in Q2 in the mid single digit percentage, with steady EBITDA growth acceleration in Q3 and Q4. This adjusted EBITDA growth target, in conjunction with continued though more moderate revenue growth, reflects an even stronger adjusted EBITDA margin expansion in FY25 of close to 100 bps, following the 30 bps adjusted EBITDA margin expansion in FY24. Coty expects FY25 adjusted EPS at the low end of its prior guidance range of $0.54-0.57, reflecting mid teens percentage growth.
Finally, Coty continues to expect FY25 free cash flow to grow by a double-digit percentage YoY to the low to mid $400M range. With the tight inventory management by retailers adding some variability on cash inflow timing, Coty remains on track to exit CY24 with leverage below 3x and continues to target leverage close to 2.5x exiting CY24.

News

Guidance

COTY

Coty Expects FY25 Adjusted EPS At The Low End Of Its Prior Guidance Range Of $0.54-$0.57 Vs $0.55 Est.

Marathon Oil (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRO#NYSE">MRO</a>) reported quarterly earnings of $0.64 per share which beat the analyst consensus estimate of $0.63 by 1.59 percent. This is a 16.88 percent decrease over earnings of $0.77 per share from the same period last year. The company reported quarterly sales of $1.79 billion which beat the analyst consensus estimate of $1.72 billion by 4.39 percent. This is a 1.21 percent decrease over sales of $1.81 billion the same period last year.

Earnings

Earnings Beats

Marathon Oil Q3 2024 Adj EPS $0.64 Beats $0.63 Estimate, Sales $1.79B Beat $1.72B Estimate

BMBL

Bumble Sees FY24 Total Revenue $1.066B-$1.072B vs $1.07B Est.

ANSS

Ansys Expects FY24 ACV Growth To Be Double-Digit

Rayonier Completes $495M Timberland Dispositions Across 200,000 Acres In Oklahoma And Washington, Enhancing Shareholder Value And Reducing Leverage To 2.8x EBITDA

Seer (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SEER#NASDAQ">SEER</a>) affirms FY2024 sales outlook from $13.00 million-15.00 million to $13.00 million-15.00 million.

SEER

Seer Affirms FY2024 Sales Guidance from $13.00M-15.00M to $13.00M-15.00M

To gain an edge, this is what you need to know today.
<figure class="wp-block-image size-large is-resized"><img decoding="async" src="https://thearorareport.com/wp-content/uploads/2024/11/2024-11-06_08h51_37.png" alt="" style="width:624px" /></figure>
<h4 class="wp-block-heading">Deploy Cash And Reduce Hedges</h4>
In addition to Trump winning the presidency, here are the key points:
<ul>
<li>Republicans have won control of the Senate.</li>
<li>Mainstream media is calling control of the House too close to call.&nbsp; However, betting markets are at a 90% probability of Republicans winning the House.</li>
<li>If Republicans win the House, there will be a complete red sweep, allowing Trump to more easily implement his agenda.</li>
<li>Trump is on track to win the popular vote. If Trump wins the popular vote, he will use that to overcome objections from Democrats.</li>
<li>The prevailing wisdom is that Trump's agenda will be highly inflationary.&nbsp; However, in The Arora Report analysis, there are several things that Trump can easily do to prevent inflation from surging again while growing the economy and bringing manufacturing back to the U.S.</li>
<li>On the other hand, if Trump embarks on a $2T cut in the Federal budget as he and Elon Musk said on the campaign trail, there is a 70% probability of a recession and the stock market falling 20% &#8211; 30%.&nbsp; Trump has said that he would appoint Musk as the efficiency czar.&nbsp; However, the probability of Trump embarking on such a program that he campaigned on is low.</li>
<li>In The Arora Report analysis, investors will need to pay attention to how Trump implements his agenda.&nbsp; The method of execution can be the difference between a 20% rise in the stock market versus a 20% drop in the stock market.&nbsp;&nbsp;</li>
</ul>
Consider deploying cash and reducing hedges.&nbsp; Consider making these moves slowly, taking advantage of opportunities that the market may present by scaling in.&nbsp; 
<h3 class="wp-block-heading">Opportunities</h3>
Please <a href="https://thearorareport.com/chart-analysis-stock-market-deploy-cash-investing-opportunities-spy-mc-11062024">click here</a> for an enlarged chart of SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) which represents the benchmark stock market index S&amp;P 500 (SPX).
Note the following:
<ul>
<li>The chart shows in the early trade the stock market is technically breaking out.&nbsp; The Arora Report will be carefully watching to see if the breakout is sustained or if it fails.</li>
<li>RSI on the chart shows there is room for the stock market to run higher.</li>
<li>Investors need to be cognizant that after the initial euphoria of Trump's win wears off, there may be a ‘sell the news' reaction.</li>
<li>In The Arora Report analysis, if there is a late ‘sell the news' reaction, the dip should be bought.&nbsp;&nbsp;</li>
<li>Here are the money flows in various asset classes in the early trade after Trump's victory:
<ul>
<li>Extremely positive in the dollar</li>
<li>Extremely positive in stocks</li>
<li>Very positive in bitcoin</li>
<li>Extremely negative in bonds</li>
<li>Negative in gold</li>
<li>Negative in oil</li>
</ul>
</li>
<li>Instead of acting out of emotion, consider taking a measured approach.&nbsp; There are many short term opportunities, but they are suitable only for aggressive investors.&nbsp; There have been a number of posts in the Real Time Feeds giving signals from both the long and short sides.&nbsp; If you are not aggressive, be patient; there will be plenty of opportunities for investors who are not aggressive.</li>
<li>In addition to short term opportunities, plenty of long term opportunities are developing.&nbsp; There is no need to rush for long term opportunities.&nbsp; Consider being patient and waiting for dips in the buy zones.</li>
<li>The FOMC is meeting.&nbsp; The Fed decision is ahead and may have a significant impact on the markets.&nbsp;</li>
</ul>
<h3 class="wp-block-heading">Magnificent Seven Money Flows</h3>
In the early trade, money flows are positive in Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), Alphabet Inc Class C (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>), Microsoft Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), NVIDIA Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), and Tesla Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>).
In the early trade, money flows are neutral in Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>).
In the early trade, money flows are negative in Meta Platforms Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>).
In the early trade, money flows are extremely positive in SPDR S&amp;P 500 ETF Trust (SPY) and Invesco QQQ Trust Series 1 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>).
<h3 class="wp-block-heading">Momo Crowd And Smart Money In Stocks</h3>
Investors can gain an edge by knowing money flows in SPY and QQQ.  Investors can get a bigger edge by knowing when smart money is buying stocks, gold, and oil.  The most popular ETF for gold is SPDR Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>).  The most popular ETF for silver is iShares Silver Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLV#NYSE">SLV</a>).  The most popular ETF for oil is United States Oil ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USO#NYSE">USO</a>).
<h3 class="wp-block-heading">Bitcoin</h3>
Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) is seeing buying.&nbsp; Crypto bulls are targeting $100,000 bitcoin in a short time.
<h3 class="wp-block-heading">Protection Band And What To Do Now</h3>
It is important for investors to look ahead and not in the rearview mirror.&nbsp; The proprietary protection band from The Arora Report is very popular.&nbsp; The protection band puts all of the data, all of the indicators, all of the news, all of the crosscurrents, all of the models, and all of the analysis in an analytical framework that is easily actionable by investors.
Consider continuing to hold good, very long term, existing positions. Based on individual risk preference, consider a protection band consisting of cash or Treasury bills or short-term tactical trades as well as short to medium term hedges and short term hedges. This is a good way to protect yourself and participate in the upside at the same time.
You can determine your protection bands by adding cash to hedges.&nbsp; The high band of the protection is appropriate for those who are older or conservative. The low band of the protection is appropriate for those who are younger or aggressive.&nbsp; If you do not hedge, the total cash level should be more than stated above but significantly less than cash plus hedges.
A protection band of 0% would be very bullish and would indicate full investment with 0% in cash.&nbsp; A protection band of 100% would be very bearish and would indicate a need for aggressive protection with cash and hedges or aggressive short selling.
It is worth reminding that you cannot take advantage of new upcoming opportunities if you are not holding enough cash.&nbsp; When adjusting hedge levels, consider adjusting partial stop quantities for stock positions (non ETF); consider using wider stops on remaining quantities and also allowing more room for high beta stocks.&nbsp; High beta stocks are the ones that move more than the market.
<h3 class="wp-block-heading">Traditional 60/40 Portfolio</h3>
Probability based risk reward adjusted for inflation does not favor long duration strategic bond allocation at this time.
Those who want to stick to traditional 60% allocation to stocks and 40% to bonds may consider focusing on only high quality bonds and bonds of five year duration or less.&nbsp; Those willing to bring sophistication to their investing may consider using bond ETFs as tactical positions and not strategic positions at this time.
The Arora Report is known for its accurate calls. The Arora Report correctly called the big artificial intelligence rally before anyone else, the new bull market of 2023, the bear market of 2022, new stock market highs right after the virus low in 2020, the virus drop in 2020, the DJIA rally to 30,000 when it was trading at 16,000, the start of a mega bull market in 2009, and the financial crash of 2008. Please click here to sign up for a free forever <a href="https://thearorareport.com/generate-wealth-newsletter-benzinga">Generate Wealth Newsletter</a>.

Market Summary

Politics

Markets

General

$BTC

AAPL

AMZN

GOOG

MSFT

NVDA

TSLA

Deplay Cash And Reduce Hedges, Short Term Opportunities At Hand, Prepare For Long Term Opportunties

Rayonier (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RYN#NYSE">RYN</a>) reported quarterly earnings of $0.12 per share which missed the analyst consensus estimate of $0.13 by 7.69 percent. The company reported quarterly sales of $195.00 million which missed the analyst consensus estimate of $210.86 million by 7.52 percent. This is a 3.27 percent decrease over sales of $201.60 million the same period last year.

Earnings Misses

Rayonier Q3 2024 Adj EPS $0.12 Misses $0.13 Estimate, Sales $195.00M Miss $210.86M Estimate

ModivCare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MODV#NASDAQ">MODV</a>) affirms FY2024 sales outlook from $2.70 billion-2.90 billion to $2.70 billion-2.90 billion.

MODV

ModivCare Affirms FY2024 Sales Guidance to $2.70B-2.90B  VS Est.2.82B

Uber Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UBER#NYSE">UBER</a>) has outperformed the market over the past 5 years by 8.88% on an annualized basis producing an average annual return of 22.73%. Currently, Uber Technologies has a market capitalization of $159.63 billion. 
Buying $1000 In UBER: If an investor had bought $1000 of UBER stock 5 years ago, it would be worth $2,739.87 today based on a price of $75.81 for UBER at the time of writing.
<h3>Uber Technologies's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730928672_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

UBER

Here's How Much $1000 Invested In Uber Technologies 5 Years Ago Would Be Worth Today

Steris (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STE#NYSE">STE</a>) reported quarterly earnings of $2.14 per share which beat the analyst consensus estimate of $2.12 by 0.94 percent.

Steris Q2 2025 Adj EPS $2.14 Beats $2.12 Estimate

Coty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COTY#NYSE">COTY</a>) reported quarterly earnings of $0.15 per share which missed the analyst consensus estimate of $0.19 by 21.05 percent. This is a 66.67 percent increase over earnings of $0.09 per share from the same period last year. The company reported quarterly sales of $1.67 billion which missed the analyst consensus estimate of $1.68 billion by 0.51 percent. This is a 1.83 percent increase over sales of $1.64 billion the same period last year.

Coty Q1 Adj $0.15 Misses $0.19 Estimate, Sales $1.67B Miss $1.68B Estimate

e.l.f. Beauty Raised Fiscal 2025 Net Sales Outlook From $1.28B-$1.3B To $1.315B-$1.335B vs $1.305B Est., Raised Adj. EPS Outlook From $3.36-$3.41 To $3.47-$3.53 vs $3.50 Est.

Ansys (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANSS#NASDAQ">ANSS</a>) reported quarterly earnings of $2.58 per share which beat the analyst consensus estimate of $1.72 by 50 percent. The company reported quarterly sales of $601.900 million which beat the analyst consensus estimate of $517.246 million by 16.37 percent. This is a 31.19 percent increase over sales of $458.795 million the same period last year.

Ansys Q3 2024 Adj. EPS $2.58 Beats $1.72 Estimate, Sales $601.900M Beat $517.246M Estimate

Nextdoor Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KIND#NYSE">KIND</a>) raises FY2024 sales outlook from $240.14 million to $245.00 million.

KIND

Nextdoor Holdings Raises FY2024 Sales Guidance from $240.14M to $245.00M

Albemarle Maintains FY24 Outlook Which Are Based On Observed Lithium Market Price Scenarios

Service Properties Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVC#NASDAQ">SVC</a>) reported quarterly earnings of $0.32 per share which missed the analyst consensus estimate of $0.38 by 15.79 percent. The company reported quarterly sales of $491.171 million which missed the analyst consensus estimate of $497.001 million by 1.17 percent. This is a 1.14 percent decrease over sales of $496.825 million the same period last year.

Service Properties Trust Q3 2024 FFO $0.32 Misses $0.38 Estimate, Sales $491.171M Miss $497.001M Estimate

Faro Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FARO#NASDAQ">FARO</a>) reported quarterly earnings of $0.21 per share which beat the analyst consensus estimate of $0.03 by 600 percent. The company reported quarterly sales of $82.563 million which beat the analyst consensus estimate of $78.972 million by 4.55 percent. This is a 4.90 percent decrease over sales of $86.813 million the same period last year.

FARO

Faro Technologies Q3 2024 Adj. EPS $0.21 Beats $0.03 Estimate, Sales $82.563M Beat $78.972M Estimate

Noodles (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NDLS#NASDAQ">NDLS</a>) lowers FY2024 sales outlook from $495.00 million-505.00 million to $487.00 million-495.00 million.

NDLS

Noodles Lowers FY2024 Sales Guidance from $495.00M-505.00M to $487.00M-495.00M  VS Est.499M

Personalis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSNL#NASDAQ">PSNL</a>) reported quarterly losses of $(0.64) per share which missed the analyst consensus estimate of $(0.36) by 77.78 percent. This is a 6.67 percent decrease over losses of $(0.60) per share from the same period last year. The company reported quarterly sales of $25.709 million which beat the analyst consensus estimate of $21.324 million by 20.56 percent. This is a 40.89 percent increase over sales of $18.247 million the same period last year.

PSNL

Personalis Q3 2024 GAAP EPS $(0.64) Misses $(0.36) Estimate, Sales $25.709M Beat $21.324M Estimate

In a report released on May 14, Jack Allen from Robert W. Baird maintained a Buy rating on MiNK Therapeutics (INKT – Research Report), with a price...

MiNK Therapeutics Poised for Growth with Strong Trial Enrollment and New Investments: A Buy Rating from Jack Allen

MiNK Therapeutics regains compliance with Nasdaq

MiNK Therapeutics GAAP EPS of -$0.07 beats by $0.02

In a report released today, Emily Bodnar from H.C. Wainwright maintained a Buy rating on MiNK Therapeutics (INKT – Research Report), with a price t...

MiNK Therapeutics' Promising Clinical Trials and Strategic Expansion Set to Enhance Stock Value

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
MiNK Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/inkt-stock-quote/">INKT</a>) just reported results for the second quarter of 2024.<ul><li>MiNK Therapeutics reported earnings per share of -7 cents. This was above the analyst estimate for EPS of -10 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/inkt-stock-earnings-mink-therapeutics-for-q2-of-2024/">INKT Stock Earnings: MiNK Therapeutics Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

INKT Stock Earnings: MiNK Therapeutics Beats EPS for Q2 2024

MiNK Therapeutics, Inc. (INKT) Q2 2024 Earnings Call Transcript

MiNK Therapeutics files to sell 4.64M shares of common stock  for holders

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Black Diamond Therapeutics (BDTX – Research Report),...

Analysts Are Bullish on These Healthcare Stocks: Black Diamond Therapeutics (BDTX), MiNK Therapeutics (INKT)

MiNK Therapeutics (INKT) announced the appointment of Dr. Robert Kadlec to its Board of Directors. Kadlec recently served as the U.S. Senate-confir...

MiNK Therapeutics appoints Robert Kadlec to board of directors

MiNK Therapeutics ( ($INKT) ) has issued an announcement. MiNK Therapeutics Inc. has appointed Dr. Robert Kadlec as a Class II director on its Boar...

Comments

MiNK Therapeutics

MiNK Therapeutics (INKT) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO